EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Survival prediction for CA19-9 non-producers with resected pancreatic cancer

Jurgis Alvikas, Ahmed Hamed, Nikhil Tirukkovalur, Sebastiaan Ceuppens, Adam Tcharni, Jiage Qian, Asmita Chopra, Genia Dubrovsky, Kenneth Lee, Amer Zureikat, Alessandro Paniccia

HPB · 2025-09 · 27 (9) · 1185-1193

DOI: 10.1016/j.hpb.2025.05.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HPB, 2025-09. Verfasst von Jurgis Alvikas und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh Medical Center, Division of Surgical Oncology, UPMC Cancer Pavilion Room 415, 5150 Centre Ave, Pittsburgh, PA, 15232, USA. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatectomy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CA 19-9 is the most commonly used biomarker for pancreatic ductal adenocarcinoma (PDAC) but prognostication is a challenge for patients with normal CA 19-9 levels. We aimed to define most important prognostic factors for overall survival in PDAC patients with normal range CA 19-9 levels. METHODS: We performed a single-center retrospective review of PDAC patients with CA 19-9 level at diagnosis

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-19-9 AntigenPancreatic NeoplasmsCarcinoma, Pancreatic DuctalPancreatectomyBiomarkers, TumorHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPredictive Value of TestsRisk FactorsNomogramsTreatment OutcomeProportional Hazards ModelsTime FactorsKaplan-Meier EstimateMultivariate AnalysisAged, 80 and overDecision Support TechniquesNeoplasm Recurrence, Local

Substanzen

CA-19-9 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • University of Pittsburgh Medical Center, Division of Surgical Oncology, UPMC Cancer Pavilion Room 415, 5150 Centre Ave, Pittsburgh, PA, 15232, USA.
  • University of Pittsburgh School of Medicine, 3550 Terrace St, Pittsburgh, PA, 15213, USA.
  • University of Pittsburgh Medical Center, Division of Surgical Oncology, UPMC Cancer Pavilion Room 415, 5150 Centre Ave, Pittsburgh, PA, 15232, USA. Electronic address: panicciaa2@upmc.edu.

Zitieren

APA

Alvikas, J., Hamed, A., Tirukkovalur, N., Ceuppens, S., Tcharni, A., Qian, J., Chopra, A., Dubrovsky, G., Lee, K., Zureikat, A., & Paniccia, A. (2025). Survival prediction for CA19-9 non-producers with resected pancreatic cancer. HPB, 27(9), 1185-1193. https://doi.org/10.1016/j.hpb.2025.05.007

Vancouver

Alvikas J, Hamed A, Tirukkovalur N, Ceuppens S, Tcharni A, Qian J, et al. Survival prediction for CA19-9 non-producers with resected pancreatic cancer. HPB. 2025;27(9):1185-1193. doi:10.1016/j.hpb.2025.05.007

BibTeX
@article{Alvikas2025,
  author = {Alvikas, Jurgis and Hamed, Ahmed and Tirukkovalur, Nikhil and Ceuppens, Sebastiaan and Tcharni, Adam and Qian, Jiage and Chopra, Asmita and Dubrovsky, Genia and Lee, Kenneth and Zureikat, Amer and Paniccia, Alessandro},
  title = {Survival prediction for CA19-9 non-producers with resected pancreatic cancer},
  journal = {HPB},
  year = {2025},
  volume = {27},
  number = {9},
  pages = {1185--1193},
  doi = {10.1016/j.hpb.2025.05.007}
}
Kostenlos starten →